Favipiravir CAS NO.259793-96-9

Favipiravir, also known as T705, or Avigan, is a selective inhibitor of viral RNA-dependent RNA polymerase with activity against many RNA viruses, influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses. Activity against enteroviruses and Rift Valley fever virus has also been demonstrated. The mechanism of its actions is thought to be related to the selective inhibition of viral RNA-dependent RNA polymerase. Favipiravir does not inhibit RNA or DNA synthesis in mammalian cells and is not toxic to them. In 2014, favipiravir was approved in Japan for stockpiling against influenza pandemics.

As a new broad-spectrum anti RNA virus drug, favipiravir was approved for marketing in Japan in March 2014 and used for antiviral treatment of influenza A and B. In addition to the influenza virus, the drug also showed good antiviral activity to a variety of RNA viruses, such as Ebola virus, sand virus, Bunia virus, rabies virus, etc. Novel coronavirus pneumonia is inhibited by the latest research.

Nanjing Yuansenthai Biological Technology Co.,Ltd. is a manufacturing company of research chemicals in China,which have been on the market since year 2010.

Headquartered in Nanjing, it has a group of research and development team with many years of rich experience in drug development and rich project management ability.The company has 6500 square meters of GMP standard workshop, Its technology portfolio comprises low temperature,high pressure reactions and continuous processing,Yuansenthai runs its technologies on dedicated and multipurpose equipments on all scales under a quality system based on the process ISO 9001:2015.Equipped with a variety of complete and advanced testing equipment, including LC/MS/MS, DSC, TGA, ICP/MS, GC/MS, HPLC, GC, H-NMR,at the same time, we keep close cooperation with some universities, ensure the smooth progress of pharmaceutical technology development research.

Yuansenthai’s one-site strategy allows reduced decision and communication pathways, thus ensuring rapid and efficient project development as well as clear and transparent communication with customers.We sincerely hope to establish long-term cooperation and common development with our customers.